Table 1.

Baseline characteristics of participants overall and according to kidney function at study entrya

CharacteristicOverall (n = 6071)CrCl <60 ml/min (n = 1757)CrCl ≥60 ml/min (n = 4314)Pb
Age (yr; mean ± SD)64 ± 1070 ± 861 ± 9<0.0001
Women (%)304525<0.0001
Asian (%)c3837390.4
Creatinine (μmol/L; median [IQR])88 (75 to 100)102 (88 to 120)83 (71 to 95)<0.0001
Creatinine clearance (ml/min; median [IQR])72 (58 to 89)50 (45 to 56)81 (70 to 96)<0.0001
Body mass index (kg/m2; mean ± SD)26 ± 424 ± 326 ± 4<0.0001
Systolic BP (mmHg; mean ± SD)147 ± 19149 ± 20146 ± 19<0.0001
Diastolic BP (mmHg; mean ± SD)86 ± 1184 ± 1186 ± 11<0.0001
Medical history (%)
    ischemic stroke7071700.6
    hemorrhagic stoke1110110.04
    stroke of unknown type574<0.0001
    transient ischemic attack2222230.5
    coronary heart diseased1620150.01
    diabetes1311130.01
    current smoker201622<0.0001
Medication (%)
    antihypertensive therapye5053490.002
    antiplatelet therapy7273720.3
    oral anticoagulants91090.4
    lipid-lowering therapy1412150.006
Study treatment regimen (%)
    active therapy5051500.3
    combination therapy or double placebos585460<0.0001
  • a IQR, interquartile range.

  • b Differences between patients with and without CKD.

  • c Participants recruited from People's Republic of China or Japan.

  • d History of myocardial infarction or coronary revascularization or of angina (supported by documented electrocardiographic or angiographic evidence).

  • e Current treated hypertension.